AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03469583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001
Description: EYP001 self administered capsules, morning, with non carbonated water
Study NCT03469583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir 1 MG
Description: Entecavir self administered tablets, morning, with non carbonated water
Study NCT03469583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir 1 MG
Description: Entecavir self administered tablets, morning, with non carbonated water
Study NCT04329351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided Bone regeneration
Description: Guided bone regeneration to ridge preservation
Study NCT04329351 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Guided Bone regeneration
Description: Guided bone regeneration to ridge preservation
Study NCT00659620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: transplantation of mesenchymal stem cell
Study NCT02153554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training civil servants on attention to violence against women
Description: The Secretary of Women of Medellin, through the ICONTEC, intends to conduct training to officials of the 22 family commissioners in Medellin. The objective of these trainings is to standardize procedures in order that women do not feel re-victimized and can forward complaints.
Study NCT01141036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol will be initiated with a 30-50 mg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
Study NCT01141036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
Study NCT04512443 — intervention group
Intervention type: DRUG
Intervention: Daflon
Description: All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).
Study NCT01723215 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active ABMT8
Description: Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
Study NCT01723215 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active ABMT4
Description: Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
Study NCT01723215 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
Study NCT02706704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Study NCT01053442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porridge fortified with either NaFeEDTA
Description: 265g maize porridge is fortified with 2.5 mg iron as NaFeEDTA.
Study NCT01053442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4
Description: Maize porridge is fortified with 2.5 mg iron as ferrous sulphate and 45 mg ascorbic acid.
Study NCT01316185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP921
Description: Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.
Study NCT00713479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline, then placebo
Description: Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability
Study NCT00713479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline, then placebo
Description: Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability
Study NCT00713479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, then varenicline
Description: Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability
Study NCT00713479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, then varenicline
Description: Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability
Study NCT00510081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxylapatite injection
Description: filler injection
Study NCT00888420 — intervention group
Intervention type: OTHER
Intervention: Performance Improvement Measures
Description: PDSA (Plan, Do, Study, Act) performance improvement measures
Study NCT02844920 — intervention group
Intervention type: DEVICE
Intervention: Intrauterine ultrasound guided radio-frequency ablation
Description: Radiofrequency ablation for the treatment of uterine fibroids
Study NCT02307487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg MMC in 90ml gel
Description: 120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
Study NCT02307487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg MMC in 90ml gel
Description: 140 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
Study NCT02307487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 mg MMC in 90ml gel
Description: 160 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
Study NCT02307487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg MMC in 60ml gel
Description: 120 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
Study NCT02307487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg MMC in 60ml gel
Description: 140 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
Study NCT02307487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 mg MMC in 60ml gel
Description: 160 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
Study NCT00227292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
Study NCT00227292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10mg per day for the first week, then 20mg per day till the end of study.
Study NCT02562079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: * biological features of the standard follow-up~* 2 more blood tube for the biological collection (serum and PBMC)
Study NCT02562079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Skin biopsies
Study NCT01087099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Treatment with albendazole
Study NCT01214694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT)
Description: Families in I-InTERACT will view 10 web-sessions (like chapters) and participate in 27 family meetings over the course of 24 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
Study NCT04139213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral naltrexone
Description: To augment care for patients receiving injectable naltrexone for the treatment of OUD and treat cravings that may arise before their scheduled injection, patients prescribed injectable naltrexone may be provided a several day supply of oral naltrexone by a study pharmacist under a collaborative pharmacy practice agreement. The expected dose of oral naltrexone will be approximately 25-50 mg daily.
Study NCT01214694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express)
Description: Families in I-InTERACT Express will view 10 web-sessions (like chapters) and participate in 14 family meetings over the course of 7 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
Study NCT01214694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Resources Comparison (IRC)
Description: Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
Study NCT01743924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: raw broccoli
Description: To eat this plant material
Study NCT02486653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~* Day 1-7: tamsulosin 0.4mg in the evening~* Day 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocol~* Day 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual \<200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function.
Study NCT02486653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~* Day 1-7: placebo in the evening~* Day 8: surgery; placebo in the evening if the subject has not yet completed the bladder management protocol~* Day 9-14: placebo in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual \<200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function.
Study NCT04049955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
Study NCT00612170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Description: 10 mg oral tablet once a day dosing
Study NCT00612170 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: 0 mg oral tablet once a day dosing
Study NCT00612170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Description: 4 mg oral tablet once a day dosing
Study NCT00612170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Description: 8 mg oral tablet once a day dosing
Study NCT02427451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bcl-2 Inhibitor GDC-0199
Description: Given PO
Study NCT02427451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT02427451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02427451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02427451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02427451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02193321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Patch
Study NCT01127659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone
Description: intramuscular every 2 weeks
Study NCT01127659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline intramuscular every 2 weeks
Study NCT04637607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupoints stimulation
Description: Noninvasive auricular acupoints stimulation with seeds
Study NCT04637607 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Auricular acupoints stimulation
Description: Noninvasive auricular acupoints stimulation with seeds
Study NCT00047671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: PDA Approved antidepressant
Study NCT00699465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.
Study NCT00699465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: enoxaparin placebo
Description: Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.
Study NCT00825279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Metal Stent
Description: Stainless steel stent
Study NCT00825279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent
Description: stent coated with the biodegradable polymer matrix hemoparin and paclitaxel
Study NCT00502814 — intervention group
Intervention type: PROCEDURE
Intervention: 3-D Optical Surface Scan
Description: 3-D digitized images of the breasts and chest will be taken over a period of five minutes.
Study NCT00502814 — intervention group
Intervention type: PROCEDURE
Intervention: Mechanical Testing
Description: A small device with a mild suction will be used to measure how the skin tends to stretch.
Study NCT00502814 — intervention group
Intervention type: PROCEDURE
Intervention: Cutaneous Ultrasound
Description: Cutaneous ultrasound using a 20 MHz machine and the skin thickness will be recorded.
Study NCT00502814 — intervention group
Intervention type: PROCEDURE
Intervention: Breast MRI and/or CT
Description: Imaging of the breasts and chest using an MRI and/or CT scan over about one hour.
Study NCT04350385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agility training
Description: In experimental group, 30 meter sprint test will be used as intervention with complexity in different stages. Test 1 was a straight sprint and tests 2-7 involved multiple changes of direction. Tests 2-7 were designed to involve progressively greater change-of-direction complexity by increasing either the angle of directional change and/or the number of changes of direction. In experimental group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd \& 6th week.
Study NCT04350385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: In group B, Conventional intervention was given to the players under the supervision of Physical Therapist that includes warm-up, strength training, agility training and cool down. In control group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd \& 6th week
Study NCT02504359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation
Study NCT02504359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given BEAM chemotherapy
Study NCT02504359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given BEAM chemotherapy
Study NCT02504359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given BEAM chemotherapy
Study NCT02504359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT02504359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given BEAM chemotherapy
Study NCT02504359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT02504359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation
Study NCT02504359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02504359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT03387436 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham-Intervention
Description: The sham intervention does not target the specific topics of the study intervention group (i.e. no special focus an ACP or end of life communication). Supportive therapy uses common factors of psychotherapy such as elicitation of affect, reflective listening, and feeling understood, but provides no explicit theoretical formulation to the patient. The therapist tries to elicit and validate the patients' affect for instance on the realization that there is no curative treatment option. Supportive therapy has been used as an unspecific control condition in several studies (Cohen et al. 2011; Markowitz et al. 1998). Patients of the sham intervention will be informed about the benefits of advance directives in general.
Study NCT03387436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study-Intervention
Description: The design of the study-intervention was influenced by dignity therapy (Chochinov et al. 2005), the End-of-life-Review (Ando et al. 2010) and barriers concerning participation of ACP identified by research (Bollig et al. 2017; Gjerberg et al. 2015). It is the goal of the study-intervention to enhance communication about death related topics of patients and their relatives/caregivers.~Our study intervention extends over six therapeutic sessions. The length of each session will be adjusted to the patients physical condition, it should not exceed 45 minutes in total.~In the first four sessions, patients and relatives will be informed about the relevance of ACP. Potential barriers for an efficient patient-caregiver communication and ACP are discussed. The intervention focuses on encouraging end-of-life communication and on jointly modifying barriers to EOL communication.~The fifth and sixth session focus on ACP based on the standardised concept of beizeiten begleiten.
Study NCT04622332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIR1-365
Description: Route of administration: oral
Study NCT04622332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Route of administration: oral
Study NCT03434171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic excercise
Description: practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
Study NCT03434171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: soy products
Description: diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
Study NCT03764891 — intervention group
Intervention type: PROCEDURE
Intervention: Uphold
Description: Uphold system in treating women with cystocele
Study NCT03764891 — intervention group
Intervention type: PROCEDURE
Intervention: Perigee
Description: Perigee system in treating women with cystocele
Study NCT03051282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Study participants in both arms will be treated with 10 mg enalapril orally once daily for seven consecutive days
Study NCT03100669 — intervention group
Intervention type: PROCEDURE
Intervention: Pectus surgery
Description: Patients undergoing surgical repair of pectus excavatum or carinatum
Study NCT00812799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oralgen
Description: 19.000 BU daily
Study NCT00812799 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: placebo control
Study NCT02140333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100mg vs. 150mg
Study NCT02140333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 100mg vs. 150mg
Study NCT04042168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: In Check Dial test
Description: In Check Dial test will test the ability to actuate the inhaler.